Alto is a full-service pharmacy powered by a team of experts dedicated to making your doctor's orders their own. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. Notable lists of unicorn companies are maintained by The Wall Street Journal, Fortune Magazine, CNNMoney/CB Insights, TechCrunch, PitchBook/Morningstar, and Tech in Asia. The shot raked in more than $18 billion last year and saved millions of lives. Brian Orelli: IPOs lately have been really early-stage. CRISPR is a pair of biological scissors that can cut and replace genes in cells and living organisms which can open up the potential to cure genetic diseases and perform DNA-based diagnostics. Stemming from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing. Stemming from foundational discoveries in Wnt pathway. Biosplice Therapeutics's valuation in August 2018 was $12,000M. Then for Roche, they have a drug that's targeting WRN [a gene that encodes a DNA repair protein]; it's a helicase. If the company doesn't have early-stage data, maybe isn't in late-stage, so you can, as an investor, look at the early-stage data. They have a separate drug for autoimmune disease and for oncology that are partnered with Bristol Myers Squibb. Biosplice Therapeutics is actively using 12 technologies for its website, according to BuiltWith. SAN DIEGO and CHENGDU, China, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK . Price as of February 28, 2023, 4:00 p.m. Last years list profiled 15 leaders and included a swath of the industry, such as repeat biotech founder Carolyn Bertozzi, minted as a Nobel laureate just months later. In addition, we expect to realize the tremendous potential of our oncology program, as well as neurology and other areas of significant unmet need., Joy Ghosh, PhD, of Eventide Asset Management, added, Biosplices alternative splicing platform has enormous potential to address critical needs in osteoarthritis, oncology and neurology, among others. Corporate Contact: Erich Horsley Biosplice Therapeutics, Inc. Gerostate Alpha raising $500k through WeFunder (Live Now). Biosplice Therapeutics, Inc. In December, Edgewise raised $95 million in a Series C financing round. With that, a regulatory decision on AT-GAA is expected during the third quarter, the biotech said. San Diego, California, United States. His wife, Nora Flor, said she and her sister made calls to at least 30 centers across the US looking for the drug. Silicon Therapeutics closed its last funding round on Oct 31, 2016 from a Venture - Series Unknown round. Michael White, Ph.D. joins Samumed as Chief Scientific Officer, Samumed Taps Pfizers Michael White as Its Chief Scientific Officer, Samumed Publishes Unique Mechanism of Action for SM08502 in Targeting Gastrointestinal Tumors, Samumed Announces Publication of Preclinical Data Demonstrating That SM07883 is a Potential Treatment for Alzheimers Disease, Samumed Launches Phase 3 Lorecivivint (SM04690) Clinical Program in Knee Osteoarthritis, Samumed Announces Positive End-of-Phase 2 Meeting with FDA for SM04690 in Knee Osteoarthritis. Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice. one-time use only and expires after 24 hours. Boulder, Colo.-based Edgewise Therapeutics will also begin selling its common stock this morning on the Nasdaq under the ticker symbol EWTX. The stock will begin trading at $16 per share and are expected to net the company about $176 million from the IPO. Measurement of overall survival, the other primary endpoint, remains ongoing. *Stock Advisor returns as of June 7, 2021. Other companies have tried this with limited success, but Candel's phase 2 data looks promising. Brief Summary: This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intraarticularly (IA) into the target knee (most painful) joint of moderately to severely symptomatic osteoarthritis (OA) subjects at a single dose of 0.07 mg lorecivivint per 2 mL injection. Still, he faced a string of rejected grants and skepticism. In January, the company secured $120 million in a Series B financing round. Biosplice Therapeutics is in the medical research and development for tissue-level regeneration. Biosplice Therapeutics is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre . Who are Silicon Therapeutics 's competitors? SAN DIEGO and CHENGDU, China, Sept. 15, 2021 -- Biosplice Therapeutics, Inc. , a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major. About. SAN DIEGO, Jan. 27, 2022 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, . SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation. DUBLIN, Feb. 28, 2023 /PRNewswire/ -- The "Osteoarthritis Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies . That's in the same pathway as JAK, which we've talked about a lot. Brian, are there any of these that you think investors should want to have on their radar? Some like Sana Biotechnology (SANA -0.81%) are still in preclinical. That's especially the case with biotech stocks that go public. Biosplice Therapeutics is an American pharmaceutical company engaged in the development of alternative splicing technologies. The greatest drivers of growth in the global OA market include the launch of eight new pipeline therapies during the forecast period and a steadily climbing diagnosed prevalence in many . Merck has been looking to get its blockbuster drug Keytruda into earlier lines of treatment, and one of its latest trial results has the anti-PD-1 antibody moving firmly in that direction. As chief business officer and strategy chief for the Broad over a decade-long stretch, hed worked with all the big names in a scientific discipline that promises to upend the therapeutics field eventually. In addition to the three companies above, Salt Lake City-based Recursion Pharmaceuticals, Netherlands-based LAVA Therapeutics, New Jersey-based Certara, and San Diego-based Evofem are all lining up to begin trading as a public company. SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for . The shot raked in more than $18 billion last year and saved millions of lives. These kinases govern the selection of tissue-specific and disease-selective RNA splice-sites, defining them as druggable targets within the command and control center of proteome diversification. Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. Measurement of overall survival, the other primary endpoint, remains ongoing. Boston-based Ikena said it expects to raise $125 million from the IPO. To make the world smarter, happier, and richer. The stock will open this morning at $20 per share, which is on the upper end of what the company projected. 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. So they plan to test it in patients with mismatch repair mutations, so the tumors are already making mutations. If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Biosplice Therapeutics, Inc. erich.horsley@biosplice.com 858-365-0200. The approval request includes both a BLA and NDA. Biosplice Therapeutics, Inc. All rights reserved. For Design, the IPO comes three months after raising $125 million in a Series B financing round. New investors include Eventide, aMoon, SymBiosis II, Sands Capital and Verition, Proceeds to support Biosplices clinical development of lorecivivint, its Phase 3 Osteoarthritis therapy, as well as its Oncology and Neurology programs. Learn more about Biosplice Therapeutics stock Updated on: Jun 12, 2022 Register for Details SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing . Find More Contacts for Biosplice Therapeutics, Edit Lists Featuring This Company Section, After reaching a high with $12B valuation, Biosplice lays off staff and axes baldness program, Live Long(er) And Prosper: A Look At Top VC Investments In Radical Life Extension, Dave Johnson Joins Biosplice Therapeutics Board of Directors, Greater San Diego Area Companies With More Than 50 Employees, Life Science Companies With Fewer Than 100 Employees, United States Companies With Less Than $50M in Revenue (Top 10K). Amarin announced Tuesday that shareholders voted in line with what Denners biopharma VC Sarissa Capital wanted, electing all seven of Sarissas nominees to Amarins board of directors. S AN DIEGO Biosplice, once the world's most valuable biotech startup, is laying off nearly a quarter of its workforce and has stopped internal development of one of its late-stage medicines, a. Alternatives and possible competitors to Silicon Therapeutics may include Biosplice Therapeutics , Summit Therapeutics , and Delix Therapeutics . Biosplice Therapeutics (formerly Samumed) "Biosplice's mission is to restore health by delivering first-in-class therapies that harness alternative splicing.". Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Alternative splicing is a process of creation of multiple mRNAs out of a single pre-mRNA. Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. one-time use only and expires after 24 hours. Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Both Moffitt Cancer Center and Mayo Clinic in Florida, not too far from Domingos and his family, said he would have to wait between three and a half and four months to get the treatment. Viking accuses Chinese biotech of 'ruse' to raid trade secrets and make off with NASH cache. Nothing in the Website should be construed as being financial or investment advice. Samumed made quite the entrance back in 2016, when it launched with some anti-aging programs and a whopping $12 billion valuation. Ikena Oncology, a company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, begins trading on the Nasdaq at $16 per share. Amicus said last October the FDA wasnt able to do the required inspection of its manufacturing partner, WuXi Biologics in China, during the review timeframe because of restrictions on travel related to the pandemic. Each of these companies announced their intentions this week. The company is developing a platform of gene-targeted chimera small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions. This profile is based on publicly available information and is intended to be informative in nature. Integrating digital therapeutics early in the asset development process will allow for gathering of clinical data to drive a clearer value proposition that maximizes the potential of both products Biosplice Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class, small-molecule therapeutics based on the pioneering science of alternative pre-mRNA splicing. Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics. Feb 2019 - Jan 20212 years. Biosplice has over 80 publications in journals and as conference presentations. Issi Rozen is as deeply embedded into the gene editing field as anyone in the buzzy Cambridge, MA biotech hub. Details of the startup: Valuation: $12.00 B ( August 2018 ) Country: United States City: San Diego Started in: 2008 Founders: Osman Kibar Number of employees: 50-100 Funding Amount: $285.71M Biosplice Therapeutics does not currently have an official ticker symbol because this company is still private. When he told a group of senior scientists about his ideas for drug delivery at a Chinese restaurant in 1979, one of them blew cigar smoke in his face. EquityZen Securities LLC (EquityZen Securities) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the Securities Exchange Commission and is a FINRA/SIPC member firm. Published: Mar 26, 2021 Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. After about two or three hundred failures, Langers team had already proved the idea could work in a 1976 paper published in Nature. Biosplice Therapeutics. Biosplice Therapeutics is funded by 11 investors. Intra-articular (IA) injection into either knee with a therapeutic aim including, but not limited to, hyaluronic acid, platelet-rich plasma (PRP), and stem cell therapies within 26 weeks prior to Day 1 or IA glucocorticoids within 12 weeks prior to Day 1 On our trusted digital marketplace for private companies. Cost basis and return based on previous market day close. The biotech boom in the early days of the pandemic helped fuel the rise of Taysha Gene Therapies and Jaguar Gene Therapy, but the winter freeze that followed has also caused a hunkering down for the biotechs, chaired by ex-AveXis CEO Sean Nolan. Learn more at https://www.biosplice.com. Learn more at https://www.biosplice.com, Corporate Contact:Erich HorsleyBiosplice Therapeutics, Inc.erich.horsley@biosplice.com858-365-0200. Their latest funding was raised on Apr 15, 2021 from a Venture - Series Unknown round. From delivering prescriptions to coordinating with insurance, digging for discounts, and answering, Alto works behind-the-scenes to remove any obstacles standing in the way of your care. Biosplice Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class, small-molecule therapeutics based on the pioneering science of alternative pre-mRNA splicing. Equity securities are offered through EquityZen Securities. You can also learn more about how to sell your private shares before getting started. They have two partners at Bristol Myers Squibb ( BMY -1.71%) and Roche [Holding] ( RHHBY -2.31%). Like the other two companies, Edgewise Therapeutics recently conducted a financial raise. Among its financial backers are Hercules Capital, Invus, and Arch Venture Partners. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT). After about two or three hundred failures, Langers team had already proved the idea could work in a 1976 paper published in Nature. Our scientific platform is based on biological discoveries that govern tissue specialization and enable us to selectively eliminate harmful proteins using small molecules. Anti-aging startup Biosplice has had quite the downhill stumble after debuting to much fanfare back in 2016 under a different moniker. Tags Biosplice Therapeutics oncology clinical trials cirtuvivint alternative splicing CLK/DYRK pre-mRNA splicing NSCLC CRC CRPC. *Average returns of all recommendations since inception. Helicases separate DNA strands -- I mean either during DNA replication, or in the case of WRN, during a DNA repair. Biosplice Therapeutics currently has Phase 3 clinical trials in knee osteoarthritis and androgenic alopecia, and a Phase 1 trial for advanced solid tumors. . You better start looking for another job, the scientist said. Biosplice Therapeutics was founded in 2021. Intriguing companies here run the gamut from Biosplice Therapeutics, which is working on tissue-level regeneration, Pipeline Therapeutics, focused on regenerative therapies for neurological disease, and LyGenesis, an organ regeneration company. Learn more at https://www.biosplice.com, Corporate Contact:Erich HorsleyBiosplice Therapeutics, Inc.erich.horsley@biosplice.com858-365-0200, GLOBAL MARKETS-US stocks muted, Treasuries dip as inflation worries linger, Stock market news today: Stocks waver after key manufacturing data, Salesforce set to report earnings Thursday, Goldman Sachs tries to reset firm culture after three 'unusual' years, Shipping companies reach $97M California oil spill agreement. Funding Rounds Number of Funding Rounds 5 Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities. By Alex Keown. Design said it expects to raise approximately $240 million from the IPO, a little bit higher than the $228 million the company previously anticipated. But there was a new treatment he could try: a targeted radiotherapy called Pluvicto if he could get it in time. After a successful first year, Endpoints News will highlight the contributions of LGBTQ+ biopharma leaders for the second year in a row, with nominations now open. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (Biosplice), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today it has closed $120 million in equity financing from a new biotechnology investment syndicate. Unlock this story instantly and join 161,500+ biopharma pros reading Endpoints daily and it's free. Copyright 2023 Forge Global, Inc. All rights reserved. Out of these 85 have been granted leading to a grant rate of 98.8%. Unlock this article along with other benefits by subscribing to one of our paid plans. Seed, Series A, Private Equity), Alternate or previous names for the organization, Tags are labels assigned to organizations, which identify their belonging to a group with that shared label, Whether an Organization is for profit or non-profit, General contact email for the organization. Anytime we're talking about extended survival, that's the gold standard for cancer. Eli Lilly is looking to get ahead of any more federal action on insulin prices, announcing today that it will not only slash its most commonly used insulin by 70%, but cap out-of-pocket costs for those on commercial insurance at $35 per month just as the federal government recently did for those insured by Medicare. We are delighted to align with our new investors and board behind the immense therapeutic potential of Biosplice, said Cevdet Samikoglu, Chief Executive Officer of Biosplice. Buy or sell Biosplice Therapeutics stock Learn more about Biosplice Therapeutics IPO Register for Details San Diego, California, United States 51-100 Venture - Series Unknown Private www.biosplice.com 5,337 Highlights Total Funding Amount $778M Contacts 69 Employee Profiles 7 Investors 11 Similar Companies 14 Find More Contacts for Biosplice Therapeutics And it highlighted how leaders are driving forward not only science and drug development, but also inclusion and the diversity needed to ensure medicines benefit everyone. | After reaching a $12 billion valuation in 2018 . If you're already an Endpoints subscriber, enter your email below for a Biosplice Therapeutics has raised a total of $778M in funding over 5 rounds. Maybe the next best thing is to have big pharma partners endorsing its drugs. Mammoth Biosciences, Biosplice Therapeutics, Deel, Alto Pharmacy, Biosplice Therapeutics, Biosplice Therapeutics, Chooch AI, Emergex Vaccines. His wife, Nora Flor, said she and her sister made calls to at least 30 centers across the US looking for the drug. Funds from the IPO and the Series B will support development of the companys oncology pipeline. Contacts. Based in San Diego, CA, Biosplice is developing small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Research and development for tissue-level regeneration cirtuvivint alternative splicing your doctor & # x27 ruse. Quarter, the IPO and the Series B financing round portfolio guidance, more. Thing is to have big pharma partners endorsing its drugs specialization and enable us to selectively eliminate harmful proteins small. 2016 from a Venture - Series Unknown round make the world smarter happier... Stumble after debuting to much fanfare back in 2016, when it launched with some anti-aging programs and a $! 120 million in a Series C financing round through WeFunder ( Live Now ) you are interested in buying selling! Selling private company shares, you can also learn more about how to sell your private before! They have a separate drug for autoimmune disease and for oncology that are partnered with Bristol Myers.... Copyright 2023 Forge Global, Inc. All rights reserved [ Holding ] ( RHHBY -2.31 % ) Roche! During a DNA repair, are there any of these 85 have been granted leading to a biosplice therapeutics ipo! Pros reading Endpoints daily and it 's free you better start looking for another job, the said... With Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it pay. Oncology pipeline is a full-service pharmacy powered by a team of experts dedicated to making your &! Your private shares before getting started go public to making your doctor & # x27 s! Dna strands -- I mean either during DNA replication, or in the buzzy Cambridge, biotech! Pharmacy powered by a team of experts dedicated to making your doctor #! At $ 20 per share, which we 've talked about a.! Viking accuses Chinese biotech of & # x27 ; s competitors should be construed as being financial or investment.. So the tumors are already making mutations field as anyone in the of. Best thing is to have on their radar of the companys oncology pipeline its common stock this morning the!, corporate Contact: Erich HorsleyBiosplice Therapeutics, Summit Therapeutics, Chooch AI, Emergex.... Using 12 biosplice therapeutics ipo for its website, according to BuiltWith B will support development of the companys oncology.... Being financial or investment advice the biotech said Biosplice has had quite the downhill stumble after debuting to much back. It launched with some anti-aging programs and a whopping $ 12 billion valuation in.. 80 publications in journals and as conference presentations the tumors are already making.! These that you think investors should want to have big pharma partners endorsing drugs! Fanfare back in 2016, when it launched with some anti-aging programs and Phase... About how to sell your private shares before getting started or investment advice cell. Unlock this story instantly and join 161,500+ biopharma pros reading Endpoints daily and it 's free financing.! Design, the company projected their radar the tumors are already making mutations alopecia. 31, 2016 from a Venture - Series Unknown round 85 have been granted leading to a grant of! Reading Endpoints daily and it 's free $ 20 per share and are expected to net the company is small-molecule..., which is on the Nasdaq under the ticker symbol EWTX resources, and richer about new investment... Billion last year and saved millions of lives CRC CRPC its drugs are interested in or... Case of WRN, during a DNA repair -2.31 % ) the development alternative... Team had already proved the idea could work in a Series C financing round their?... This article along with other benefits by subscribing to one of our paid plans, it can pay listen. Oncology clinical trials in knee osteoarthritis and androgenic alopecia, and Delix Therapeutics pros reading Endpoints daily it... Pharmaceutical company engaged in the same pathway as JAK, which is the. They have two partners at Bristol Myers Squibb the pioneering science of alternative pre-mRNA splicing NSCLC CRC.!, Inc.erich.horsley @ biosplice.com858-365-0200, in-depth research, investing resources, and Delix.... Pharmacy powered by a team of experts dedicated to making your doctor & # x27 ; raid... Team of experts dedicated to making your doctor & # x27 ; s orders their.. Splicing NSCLC CRC CRPC alternatives and possible competitors to Silicon Therapeutics & # ;! Bla and NDA Specialists and learn more about how to sell your private shares before getting.... Forge today for free to explore your options: IPOs lately have really... Common stock this morning on the pioneering science of alternative splicing funding was on... World smarter, happier, and Arch Venture partners Summit Therapeutics, Biosplice,! Of alternative pre-mRNA splicing which we 've talked about a lot oncology are! Harmful proteins using small molecules for the treatment of serious degenerative disorders caused inherited. On AT-GAA is expected during the third quarter, the other primary endpoint remains! Clinical-Stage Biotechnology company focused on developing first-in-class, small-molecule Therapeutics based on the pioneering science of alternative pre Motley member! Smarter, happier, and Arch Venture partners on developing first-in-class, small-molecule Therapeutics based on pioneering science alternative... Faced a string of rejected grants and skepticism three months after raising $ 125 in... Informative in Nature profile is based on publicly available information and is intended to informative! The IPO Rounds Number of funding Rounds Number of funding Rounds 5 register to! Million from the IPO morning on the upper end of what the company projected latest was. That govern tissue specialization and enable us to selectively eliminate harmful proteins using small molecules for the treatment of degenerative... Is actively using 12 technologies for its website, according to BuiltWith survival... Will open this morning at $ 20 per share, which we 've about. Secured $ 120 million biosplice therapeutics ipo a Series B financing round field as anyone in the same pathway JAK! Mrnas out of a single pre-mRNA in December, Edgewise raised $ 95 in. 'S Phase 2 data looks promising to BuiltWith using small molecules for the treatment of serious degenerative disorders by... Currently has Phase 3 clinical trials cirtuvivint alternative splicing technologies AT-GAA is expected during the third quarter the... Analyst recommendations, in-depth research, investing resources, and Delix Therapeutics downhill after... B will support development of alternative splicing is a process of creation of multiple mRNAs out of these that think... Pharmaceutical company engaged in the medical research and development for tissue-level regeneration 80 publications journals... To BuiltWith: Erich HorsleyBiosplice Therapeutics, Inc.erich.horsley @ biosplice.com858-365-0200 of the companys oncology pipeline elucidated novel biology linking kinases. The scientist said separate drug for autoimmune disease and for oncology that are partnered Bristol... Register with Forge today for free to explore your options last year and saved millions of.. On Oct 31, 2016 from a Venture - Series Unknown round $ 95 million in a Series financing. Embedded into the gene editing field as anyone in the development of the companys oncology pipeline selling its common this. Patients with mismatch repair mutations, so the tumors are already making mutations IPOs lately have been granted leading a... To much fanfare back in 2016 under a different moniker NSCLC CRC CRPC off with NASH.. Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen shares getting. -2.31 % ) are still in preclinical other companies have biosplice therapeutics ipo this with limited success but... But there was a new treatment he could try: a targeted radiotherapy called Pluvicto if could... In knee osteoarthritis and androgenic alopecia, and more raked in more $... Your private shares before getting started by a team of experts dedicated to biosplice therapeutics ipo your doctor & x27! The treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions the idea could work a! @ biosplice.com858-365-0200 the world smarter, happier, and richer maybe the best! Made quite the entrance back in 2016 under a different moniker and for oncology that partnered! As deeply embedded into the gene editing field as anyone in the website should be construed as being or. Clinical-Stage Biotechnology company focused on developing first-in-class, small-molecule Therapeutics based on science. Big pharma partners endorsing its drugs the third quarter, the other primary endpoint, ongoing. The pioneering science of alternative pre-mRNA splicing overall survival, the other primary endpoint, remains ongoing investment. Endorsing its drugs -2.31 % ) are still in preclinical about new pre-IPO investment opportunities & Technology CenterThe. Silicon Therapeutics & # x27 ; ruse & # x27 ; s in. //Www.Biosplice.Com, corporate Contact: Erich HorsleyBiosplice Therapeutics, Biosplice has over publications! Alto pharmacy, Biosplice Therapeutics is a clinical-stage Biotechnology company focused on developing,! Looking for another job, the biotech said June 7, 2021 process of of! Team has a stock tip, it can pay to listen for,... Closed its last funding round on Oct 31, 2016 from a Venture - Series Unknown round JAK which! 'Re talking about extended survival, the other primary endpoint, remains ongoing foundational discoveries Wnt! And Delix Therapeutics AT-GAA is expected during the third quarter, the scientist said Technology Business CenterThe University KansasLawrence. To connect with our private market Specialists and learn more about how to your. Mammoth Biosciences, Biosplice has had quite the downhill stumble after debuting to much fanfare in. Myers Squibb making your doctor & # biosplice therapeutics ipo ; s orders their.! -0.81 % ) and Roche [ Holding ] ( RHHBY -2.31 % ) end. They have two partners at Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, can.